CeloNova BioSciences CEO Urges More Heart, More Passion, More Honesty, and All Urgency in Developing Medical Devices

NEWNAN, Georgia, December 1 - CeloNova BioSciences, Inc., a provider of specialty surface treatments
for medical devices and of specialty implants, today announced that President
and Chief Executive Officer, Thomas A. Gordy, will give an opening address
for the Technology Parade at the Innovations in Cardiovascular Interventions
Conference in Tel Aviv, Israel. "We must leave the era of petty self-interest
behind and focus the rich intellectual resources of the health care industry
toward collaboration, innovation, and rapid market entry. We need more heart,
more passion, and more integrity. With laser-like focus, we can truly heal
the world," said Gordy. "The international faculty at ICI is renowned for
spotlighting transformative technology."

    (Logo: www.newscom.com/cgi-bin/prnh/20081001/CLW080LOGO-b )
    (Photo: www.newscom.com/cgi-bin/prnh/20081007/CLTU035-a )
    (Photo: www.newscom.com/cgi-bin/prnh/20081001/CLW080-c )

About CeloNova BioSciences: Headquartered in Newnan, Georgia, CeloNova
BioSciences, Inc., is a developer of novel medical devices that are enhanced
by one of the Company's proprietary materials, Polyzene(R)-F, a lubricious,
anti-thrombotic, anti-inflammatory, and bacterial-resistant surface treatment
for implanted medical devices. The Company's current products include
Embozene(TM) Color-Advanced Microspheres and the CATANIA(TM) Coronary Stent
System with NanoThin Polyzene(R)-F. Both products are CE Marked. Embozene(TM)
Microspheres have been approved by the FDA for the treatment of
hypervascularized tumors and arteriovenous malformations. For more
information, please visit www.celonova.com

About Innovations in Cardiovascular Interventions: The ICI meeting for
interventional cardiologists, innovators, and industry will be held December
6-8, in Tel-Aviv, Israel. It is a continuation of the series of
interventional cardiology conferences held in Israel since 1995. The upcoming
meeting will focus on innovative technology, therapies, and research at
various levels of development, with thematic live case presentations to
present the impact of these technologies on current and future therapy.

Contact: Theresa Wilson +1-770-502-0304; +1-678-895-6486

Theresa Wilson +1-770-502-0304; +1-678-895-6486